Presentation is loading. Please wait.

Presentation is loading. Please wait.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting.

Published byJonathan Copeland Modified over 9 years ago

Similar presentations

Presentation on theme: "© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting."— Presentation transcript:

1 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

2 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

3 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

4 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

5 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

6 © 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

Download ppt "© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting."

Similar presentations

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:803-814 Five-year clinical follow-up of unprotected left main bifurcation lesion.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Five-year clinical follow-up of unprotected left main bifurcation lesion.
Children Aged 5 to

Children Aged 5 to
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Safety and Efficacy of DES in Women: An Individual Patient-Level Pooled Analysis of 26 Randomized Trials Including 11,557 Women Roxana Mehran, MD, FESC,

Safety and Efficacy of DES in Women: An Individual Patient-Level Pooled Analysis of 26 Randomized Trials Including 11,557 Women Roxana Mehran, MD, FESC,
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:732-742 Percutaneous, transendocardial injection of bone marrow-derived mononuclear.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear.
© 2012 EuroIntervention. All rights reserved. EuroInterv.2007;3:256-261 \'Fused-Gold\' vs. \'Bare\' stainless steel NIRflex stents of the same geometric.

© 2012 EuroIntervention. All rights reserved. EuroInterv.2007;3: \'Fused-Gold\' vs. \'Bare\' stainless steel NIRflex stents of the same geometric.
1 Financial Mathematics Clicker review session, Final.

1 Financial Mathematics Clicker review session, Final.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.

Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;7:225-233 Correlation between fractional flow reserve and intravascular ultrasound.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;7: Correlation between fractional flow reserve and intravascular ultrasound.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:855-865 Comparison of intravascular ultrasound versus angiography-guided drug-eluting.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Comparison of intravascular ultrasound versus angiography-guided drug-eluting.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.

BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5:580-588 A comparison of patient characteristics and 30-day mortality outcomes after.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
8.1.4 Can it still be factored? Factoring Completely I can factor out a common factor.

8.1.4 Can it still be factored? Factoring Completely I can factor out a common factor.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;6:1037-1045 First-in-man evaluation of intravascular optical frequency domain imaging.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;6: First-in-man evaluation of intravascular optical frequency domain imaging.
PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.

PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.

Similar presentations

Ads by Google